Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis

Cotter, 2020, Nonalcoholic fatty liver disease 2020: the state of the disease, Gastroenterology, 158, 1851, 10.1053/j.gastro.2020.01.052 Younossi, 2019, Non-alcoholic fatty liver disease - a global public health perspective, J Hepatol, 70, 531, 10.1016/j.jhep.2018.10.033 Estes, 2018, Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease, Hepatology, 67, 123, 10.1002/hep.29466 Mantovani, 2020, Complications, morbidity and mortality of nonalcoholic fatty liver disease, Metabolism, 111S Younossi, 2019, Burden of illness and economic model for patients with nonalcoholic steatohepatitis in the United States, Hepatology, 69, 564, 10.1002/hep.30254 Targher, 2021, Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach, Lancet Gastroenterol Hepatol, 6, 578, 10.1016/S2468-1253(21)00020-0 Targher, 2016, Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis, J Hepatol, 65, 589, 10.1016/j.jhep.2016.05.013 Wu, 2016, Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis, Sci Rep, 6 Liu, 2019, Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis, Sci Rep, 9 Page, 2021, The PRISMA 2020 statement: an updated guideline for reporting systematic reviews, BMJ, 372, n71, 10.1136/bmj.n71 Stroup, 2000, Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group, JAMA, 283, 2008, 10.1001/jama.283.15.2008 2019 Higgins, 2002, Quantifying heterogeneity in a meta-analysis, Stat Med, 21, 1539, 10.1002/sim.1186 Hamaguchi, 2007, Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease, World J Gastroenterol, 13, 1579, 10.3748/wjg.v13.i10.1579 Jepsen, 2003, Prognosis of patients with a diagnosis of fatty liver—a registry-based cohort study, Hepatogastroenterology, 50, 2101 Targher, 2007, Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients, Diabetes Care, 30, 2119, 10.2337/dc07-0349 Haring, 2009, Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels, Hepatology, 50, 1403, 10.1002/hep.23135 Adams, 2010, Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study, Am J Gastroenterol, 105, 1567, 10.1038/ajg.2010.18 Lazo, 2011, Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study, BMJ, 343, 10.1136/bmj.d6891 Ekstedt, 2015, Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up, Hepatology, 61, 1547, 10.1002/hep.27368 Wild, 2018, Cardiovascular disease, cancer, and mortality among people with type 2 diabetes and alcoholic or nonalcoholic fatty liver disease hospital admission, Diabetes Care, 41, 341, 10.2337/dc17-1590 Vilar-Gomez, 2018, Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study, Gastroenterology, 155, 443, 10.1053/j.gastro.2018.04.034 Alexander, 2019, Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults, BMJ, 367 Sinn, 2019, Non-alcoholic fatty liver disease and the incidence of myocardial infarction: a cohort study, J Gastroenterol Hepatol, 35, 833, 10.1111/jgh.14856 Henson, 2020, Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease, Aliment Pharmacol Ther, 51, 728, 10.1111/apt.15660 Labenz, 2020, Impact of NAFLD on the incidence of cardiovascular diseases in a primary care population in Germany, Dig Dis Sci, 65, 2112, 10.1007/s10620-019-05986-9 Meyersohn, 2021, Association of hepatic steatosis with major adverse cardiovascular events, independent of coronary artery disease, Clin Gastroenterol Hepatol, 19, 1480, 10.1016/j.cgh.2020.07.030 Zhou, 2012, Natural course of nonalcoholic fatty liver disease in southern China: a prospective cohort study, J Dig Dis, 13, 153, 10.1111/j.1751-2980.2011.00571.x El Azeem, 2013, Association between nonalcoholic fatty liver disease and the incidence of cardiovascular and renal events, J Saudi Heart Assoc, 25, 239, 10.1016/j.jsha.2013.07.004 Kim, 2013, Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States, Hepatology, 57, 1357, 10.1002/hep.26156 Pisto, 2014, Fatty liver predicts the risk for cardiovascular events in middle-aged population: a population-based cohort study, BMJ Open, 4, 10.1136/bmjopen-2014-004973 Pickhardt, 2014, Natural history of hepatic steatosis: observed outcomes for subsequent liver and cardiovascular complications, AJR Am J Roentgenol, 202, 752, 10.2214/AJR.13.11367 Wong, 2016, Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: a prospective cohort study, Hepatology, 63, 754, 10.1002/hep.28253 Moon, 2015, Association between nonalcoholic fatty liver disease and carotid artery inflammation evaluated by 18F-fluorodeoxyglucose positron emission tomography, Angiology, 66, 472, 10.1177/0003319714537872 Emre, 2015, Impact of nonalcoholic fatty liver disease on myocardial perfusion in nondiabetic patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction, Am J Cardiol, 116, 1810, 10.1016/j.amjcard.2015.09.021 Zeb, 2016, Nonalcoholic fatty liver disease and incident cardiac events: the multi-ethnic study of atherosclerosis, J Am Coll Cardiol, 67, 1965, 10.1016/j.jacc.2016.01.070 Fracanzani, 2016, Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up, Atherosclerosis, 246, 208, 10.1016/j.atherosclerosis.2016.01.016 Yoshitaka, 2017, Nonoverweight nonalcoholic fatty liver disease and incident cardiovascular disease: a post hoc analysis of a cohort study, Medicine (Baltimore), 96, 10.1097/MD.0000000000006712 Hwang, 2018, Nonalcoholic fatty liver disease associates with increased overall mortality and death from cancer, cardiovascular disease, and liver disease in women but not men, Clin Gastroenterol Hepatol, 16, 1131, 10.1016/j.cgh.2017.11.026 Vita, 2019, Association between nonalcoholic fatty liver disease at CT and coronary microvascular dysfunction at myocardial perfusion PET/CT, Radiology, 291, 330, 10.1148/radiol.2019181793 Hagstrom, 2019, Cardiovascular risk factors in non-alcoholic fatty liver disease, Liver Int, 39, 197, 10.1111/liv.13973 Liu, 2019, Impact of non-alcoholic fatty liver disease on cardiovascular outcomes in patients with stable coronary artery disease: a matched case-control study, Clin Transl Gastroenterol, 10, 10.14309/ctg.0000000000000011 Allen, 2019, Women with nonalcoholic fatty liver disease lose protection against cardiovascular disease: a longitudinal cohort study, Am J Gastroenterol, 114, 1764, 10.14309/ajg.0000000000000401 Caruso, 2019, Fatty liver and mortality: a cohort population study in South Italy, BMJ Open, 9, 10.1136/bmjopen-2018-027379 Chang, 2020, Alcoholic and nonalcoholic fatty liver disease and incident hospitalization for liver and cardiovascular diseases, Clin Gastroenterol Hepatol, 18, 205, 10.1016/j.cgh.2019.05.004 Ichikawa, 2021, Prognostic value of non-alcoholic fatty liver disease for predicting cardiovascular events in patients with diabetes mellitus with suspected coronary artery disease: a prospective cohort study, Cardiovasc Diabetol, 20, 8, 10.1186/s12933-020-01192-4 Xu, 2021, Severity of nonalcoholic fatty liver disease and risk of future ischemic stroke events, Stroke, 52, 103, 10.1161/STROKEAHA.120.030433 Baratta, 2020, Nonalcoholic fatty liver disease and fibrosis associated with increased risk of cardiovascular events in a prospective study, Clin Gastroenterol Hepatol, 18, 2324, 10.1016/j.cgh.2019.12.026 Simon, 2021, Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort, Gut, 70, 1375, 10.1136/gutjnl-2020-322786 Karajamaki, 2017, Non-alcoholic fatty liver disease with and without metabolic syndrome: different long-term outcomes, Metabolism, 66, 55, 10.1016/j.metabol.2016.06.009 Shah, 2017, Pericardial, but not hepatic, fat by CT is associated with CV outcomes and structure: the Multi-Ethnic Study of Atherosclerosis, JACC Cardiovasc Imaging, 10, 1016, 10.1016/j.jcmg.2016.10.024 Hagstrom, 2017, Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD, J Hepatol, 67, 1265, 10.1016/j.jhep.2017.07.027 Baik, 2019, Liver fibrosis, not steatosis, associates with long-term outcomes in ischaemic stroke patients, Cerebrovasc Dis, 47, 32, 10.1159/000497069 Lauridsen, 2018, Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals, Eur Heart J, 39, 385, 10.1093/eurheartj/ehx662 Niriella, 2020, Metabolic syndrome, but not non-alcoholic fatty liver disease, increases 10-year mortality: a prospective, community-cohort study, Liver Int, 40, 101, 10.1111/liv.14237 Lee, 2020, Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study, Clin Gastroenterol Hepatol, 2020 Motamed, 2020, Non-alcoholic fatty liver disease is not independent risk factor for cardiovascular disease event: a cohort study, World J Hepatol, 12, 323, 10.4254/wjh.v12.i6.323 Paik, 2020, The impact of modifiable risk factors on the long-term outcomes of non-alcoholic fatty liver disease, Aliment Pharmacol Ther, 51, 291, 10.1111/apt.15580 Niriella, 2021, Outcomes of NAFLD and MAFLD: results from a community-based, prospective cohort study, PLoS One, 16, 10.1371/journal.pone.0245762 Targher, 2021, The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments, Nat Rev Gastroenterol Hepatol, 18, 599, 10.1038/s41575-021-00448-y Taylor, 2020, Association between fibrosis stage and outcomes of patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis, Gastroenterology, 158, 1611, 10.1053/j.gastro.2020.01.043 Mantovani, 2021, Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals, Gut, 70, 962, 10.1136/gutjnl-2020-322572 Mantovani, 2020, Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis, Gut Mantovani, 2019, Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated meta-analysis, Liver Int, 39, 758, 10.1111/liv.14044 Mantovani, 2021, Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies, Gut, 10.1136/gutjnl-2020-322572 Adams, 2017, Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases, Gut, 66, 1138, 10.1136/gutjnl-2017-313884 Ghouri, 2010, Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data, Hepatology, 52, 1156, 10.1002/hep.23789 Targher, 2020, NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications, Gut, 69, 1691, 10.1136/gutjnl-2020-320622 Henson, 2020, Is nonalcoholic fatty liver disease not a risk factor for cardiovascular disease: not yet time for a change of heart, Hepatology, 71, 1867, 10.1002/hep.31156 Stahl, 2019, Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review, J Am Coll Cardiol, 73, 948, 10.1016/j.jacc.2018.11.050 Morrison, 2019, Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: a meta-analysis with bias analysis, Liver Int, 39, 557, 10.1111/liv.13994 Targher, 2020, NAFLD, and cardiovascular and cardiac diseases: factors influencing risk, prediction and treatment, Diabetes Metab Liu, 2017, Exome-wide association study of plasma lipids in >300,000 individuals, Nat Genet, 49, 1758, 10.1038/ng.3977 Eslam, 2018, Genetics and epigenetics of NAFLD and NASH: clinical impact, J Hepatol, 68, 268, 10.1016/j.jhep.2017.09.003